Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
This report is released for strategic visibility purposes only. All other reports remain confidential. If this depth of analysis aligns with your diligence standards, contact us for access to the full Intelligence Library.
This report delivers a full-spectrum analysis of Aptamer Sciences, Inc. (KOSDAQ: 291650) and its lead asset, AST-201, a GPC3-targeting Aptamer–Drug Conjugate (ApDC) currently in Phase 1 clinical testing.
Unlike traditional due diligence, this dossier highlights red flags in scientific validation, patent ownership, and clinical design intelligence brief.
🚩 No verifiable patents linked to AST-201 or the ApDC® platform under Aptamer Sciences
⏳ Unusually long Phase 1 timeline (2025–2028) with 70 patients – outlier vs. industry benchmarks
📉 High burn rate with limited cash runway, risking underfunded trial execution
🔬 CEO’s only scientific publication (2014) is methodologically irrelevant to current programs
Many ApDCs claim scientific novelty — few can prove it.
This report helps VCs, BD teams, and biotech analysts avoid technology shells, where platform, patents, and data do not align.
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com
This report is released for strategic visibility purposes only. All other reports remain confidential. If this depth of analysis aligns with your diligence standards, contact us for access to the full Intelligence Library.
This report delivers a full-spectrum analysis of Aptamer Sciences, Inc. (KOSDAQ: 291650) and its lead asset, AST-201, a GPC3-targeting Aptamer–Drug Conjugate (ApDC) currently in Phase 1 clinical testing.
Unlike traditional due diligence, this dossier highlights red flags in scientific validation, patent ownership, and clinical design intelligence brief.
🚩 No verifiable patents linked to AST-201 or the ApDC® platform under Aptamer Sciences
⏳ Unusually long Phase 1 timeline (2025–2028) with 70 patients – outlier vs. industry benchmarks
📉 High burn rate with limited cash runway, risking underfunded trial execution
🔬 CEO’s only scientific publication (2014) is methodologically irrelevant to current programs
Many ApDCs claim scientific novelty — few can prove it.
This report helps VCs, BD teams, and biotech analysts avoid technology shells, where platform, patents, and data do not align.
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com